Dougal - I agree entirely with your post. As with any company there are products under development for the long term (insulin) and the short term.
But the key difference b/n POH and so many other Biotechs that are listed here is we have a rich and diverse pipeline in the clinic. We are not a "one trick pony" relying on success from one idea. Should we have a set back in one area as we did with nestle last year when we didnt achieve Nestles markers - we then continue on with our other programs. That should instill plenty of confidence in this stock for newcomers to this story
KC
once a week insulin drug, page-10
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(16.7%) |
Mkt cap ! $7.923M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $3.226K | 1.116M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 52 | 92468918 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 76402411 | 25 |
View Market Depth
| Last trade - 12.50pm 06/09/2024 (20 minute delay) ? |
| AVE (ASX) Chart |